Last reviewed · How we verify
target treatment
target treatment is a CDK4/6 inhibitor Small molecule drug developed by Institut Bergonié. It is currently FDA-approved for Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, Hormone receptor-positive, HER2-negative early breast cancer.
This drug targets the CDK4/6 pathway to inhibit cancer cell proliferation.
Target treatment is a small molecule intervention that has been studied in various clinical trials for conditions such as COPD, myocardial infarction, and atrial fibrillation. The treatment has been tested in combination with other medications, including DOAC and clopidogrel, and as a monotherapy, but its exact mechanism is diagnostic rather than therapeutic.
At a glance
| Generic name | target treatment |
|---|---|
| Sponsor | Institut Bergonié |
| Drug class | CDK4/6 inhibitor |
| Target | CDK4/6 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Palbociclib works by binding to the CDK4/6 enzymes, preventing them from phosphorylating the retinoblastoma protein (Rb) and thereby inhibiting cell cycle progression. This leads to a decrease in cancer cell proliferation and an increase in apoptosis. The drug is most effective in combination with endocrine therapy for hormone receptor-positive breast cancer.
Approved indications
- Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer
- Hormone receptor-positive, HER2-negative early breast cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Leukopenia
- Thrombocytopenia
Key clinical trials
- The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health. (NA)
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) (PHASE2)
- A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN） (PHASE1)
- Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer (NA)
- Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) (PHASE2)
- Effect of Scalp Block on Intraoperative Hemodynamics and Postoperative Pain in Craniotomy Patients" (NA)
- Reducing Symptom Burden Through Physical Exercise in Melanoma Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- target treatment CI brief — competitive landscape report
- target treatment updates RSS · CI watch RSS
- Institut Bergonié portfolio CI
Frequently asked questions about target treatment
What is target treatment?
How does target treatment work?
What is target treatment used for?
Who makes target treatment?
What drug class is target treatment in?
What development phase is target treatment in?
What are the side effects of target treatment?
What does target treatment target?
Related
- Drug class: All CDK4/6 inhibitor drugs
- Target: All drugs targeting CDK4/6
- Manufacturer: Institut Bergonié — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer
- Indication: Drugs for Hormone receptor-positive, HER2-negative early breast cancer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing